Skip to main content
TipRanks
Go Ultimate75% OFF

Zevra Therapeutics (1GDA) Q3 2026 Earnings Report

1 Followers

DE:1GDA Q3 2026 EPS Results

Actual EPS
EUR 0.24
Consensus EPS
EUR 0.14
Beat/Miss
Beat by +EUR 0.09
One Year Ago EPS
-EUR 0.01

DE:1GDA Q3 2026 Revenue Results

Actual Revenue
EUR 34.25M
Expected Revenue
EUR 33.64M
Beat/Miss
Beat by +EUR 613.30K
YoY Revenue Growth
+44.86%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/03/2026
Time
After Close
Conference Call
Tuesday, November 3, 2026
DE:1GDA Upcoming Earnings

Zevra Therapeutics's next earnings date is estimated for March 10, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:1GDA Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 03, 2026|% Change Since:-6.77%|
Earnings Call Sentiment|Positive

The call was strongly positive, driven by 45% year-over-year revenue growth, accelerating MIPLYFFA sales, 197 cumulative prescription enrollment forms, high retention and refill rates, expanding payer coverage, increased disease awareness, a strong cash position and progress across the pipeline. The principal challenges were the unresolved European regulatory reexamination, increased operating expenses, the early stage of the celiprolol event-driven trial and ongoing difficulty diagnosing NPC.

Company Guidance

Zevra expects to file an sNDA in the first quarter of 2027 for patients less than 24 months of age, expects the CHMP’s opinion in the fourth quarter, and now anticipates a decision from the USPTO in 2027; it also intends to have a follow-up discussion with the FDA in the first half of 2027 regarding the DiSCOVER trial. Management said the potential label expansion represents “probably in the ballpark of 5%” additional patients, and that, “with the modest expansion next year,” it does not foresee “any meaningful increases from this year” in SG&A and would “not look to make major changes” to marketing spend going forward.

  • Strong Third-Quarter Revenue GrowthTotal net revenue was $37.8 million in Q3 2026, up $11.7 million or 45% from $26.1 million in Q3 2025. Revenue included $34 million from MIPLYFFA U.S. net sales, $0.2 million from OLPRUVA and $3.6 million in global Expanded Access Program net reimbursements.
  • MIPLYFFA Sales Continued to AccelerateMIPLYFFA U.S. revenue grew 12.6% compared with Q2 2026 and 52% compared with Q3 2025. Management said the company has reached a large portion of the diagnosed U.S. patient population during the first seven full quarters after launch.
  • Growing Patient Enrollment and Market OpportunityZevra received 13 MIPLYFFA prescription enrollment forms in Q3, bringing cumulative enrollment since launch to 197. The forms included both adult and pediatric patients and a meaningful proportion of newly diagnosed patients. Management believes the U.S. diagnosed population may be higher than the previous estimate of 300 to 350 patients, with the broader prevalent population estimated at approximately 900 patients.
  • High Patient Retention and Refill RatesThe company reported high patient retention and refill rates consistent with its Expanded Access Program experience. Management said reimbursement rates remained strong and that it did not see a change in those trends.
  • Broad Payer CoverageMIPLYFFA payer coverage was 69%, with most remaining patients receiving coverage through medical exception pathways. Management attributed the coverage to the strength of the clinical data and ongoing engagement with payers.
  • Disease Awareness Efforts Increased Digital ReachThe disease awareness website recorded a 123% quarter-over-quarter increase in visits, rising from 25,000 in Q2 to nearly 56,000 in Q3. The increase was partly driven by the launch of the NPC Knowledge Hub. Zevra also reported increased display impressions, search clicks and click-through rates across its digital channels.
  • Expanded Commercial and Diagnostic InitiativesZevra continued its Learn NPC, Read Between the Signs campaign, collaborations with genetic testing providers, proprietary analytics to identify healthcare professionals, and its Expert Connect clinician education program. The company modestly expanded its customer-facing team to reach community practices outside centers of excellence and said it was able to expand the team quickly in response to claims-data findings.
  • Potential Pediatric Label ExpansionA pediatric substudy evaluating arimoclomol with miglustat in infants 6 months to less than 24 months found the treatment was well tolerated with no new observed safety signals through up to 36 months of treatment. Following a Type B meeting with the FDA, Zevra expects to file an sNDA in the first quarter of 2027 to potentially expand the label to patients younger than 24 months.
  • MIPLYFFA Intellectual Property ProtectionMIPLYFFA is covered by Orange Book-listed patents with expiration dates extending to 2041 and has U.S. orphan drug exclusivity for NPC through 2031. Zevra is also pursuing a patent term extension and now anticipates a USPTO decision in 2027.
  • Global Expanded Access Program ExpansionThe global Expanded Access Program enrolled 134 patients and includes compassionate-use and named-patient reimbursement programs. During the quarter, Zevra expanded the program to an additional territory and continued evaluating further opportunities to expand global access.
  • Progress in the Celiprolol vEDS TrialThe Phase 3 DiSCOVER trial enrolled six new patients in Q3, bringing total enrollment to 72. The trial has an interim analysis trigger at 28 events, and four confirmed events had occurred through the end of Q3. Zevra held a second Type C meeting with the FDA regarding a potential submission strategy that would include retrospective real-world data sets.
  • Strong Cash PositionCash, cash equivalents and investments totaled $270.9 million as of September 30, 2026, an increase of approximately $10.7 million from June 30, 2026. Management said the balance sheet provides flexibility to pursue MIPLYFFA opportunities, broaden global access and advance the development pipeline.
  • Return to ProfitabilityNet income was $19.2 million, or $0.31 per basic share and $0.26 per diluted share, compared with a net loss of $0.5 million, or $0.01 per basic and diluted share, in Q3 2025.
  • Additional NPC Market ValidationManagement viewed Shionogi's acquisition of IntraBio and additional companies entering the NPC market positively, saying the activity validates the market opportunity, can increase disease awareness and diagnosis, and reinforces MIPLYFFA's foundational position as the only drug with data showing use in combination with miglustat.
  • Potential Longer-Term Franchise ExpansionZevra said it is exploring additional indications and other opportunities to maximize the MIPLYFFA franchise and provide further optionality for patients with NPC, although it did not provide specific details.

DE:1GDA Earnings History

DE:1GDA earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 10, 20272026 (Q4)0.17-0.17――
Nov 03, 20262026 (Q3)0.140.24-0.012700.00% (+0.24)
Aug 05, 20262026 (Q2)0.100.131.1-88.43% (-0.97)
May 06, 20262026 (Q1)0.070.54-0.051100.00% (+0.60)
Mar 09, 20262025 (Q4)0.050.17-0.61128.36% (+0.78)
Nov 05, 20252025 (Q3)-0.03-0.01-0.6398.55% (+0.62)
Aug 12, 20252025 (Q2)2.051.10-0.44352.08% (+1.53)
May 13, 20252025 (Q1)-0.16-0.05-0.3685.00% (+0.31)
Mar 11, 20252024 (Q4)-0.36-0.61-0.46-31.37% (-0.15)
Nov 12, 20242024 (Q3)-0.37-0.63-0.36-72.50% (-0.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed